2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Biological activity
Description
CAS NO.：153436-53-4 Product Name：N-(3-Chlorophenyl)-6,7-dimethoxyquinazolin-4-amine Synonyms：4-Quinazolinamine,N-(3-chlorophenyl)-6,7-dimethoxy-;Tyrphostin AG 1478;AG 1478 HYDROCHLORIDE;AG1478;AG-1478;AG-1478 (Tyrphostin AG-1478);N-(3-chlorophenyl)-6,7-dimethoxy-4-Quinazolinamine;N-(3-chlorophenyl)-6,7-dimethoxyquinazolin-4-amine;Tyrphostin AG 1478 (AG 1478,NSC-693255);AG-1478 hydrochloride;NSC693255;Tyrphostin;Tyrphostin AG-1478;(3-Chlorophenyl)(6,7-dimethoxyquinazolin-4-yl)amine;AG1478HCl;AG-1478 (NSC-693255);4-(3-CHLOROANILINO)-6,7-DIMETHOXYQUINAZOLINE HCL;NSC 693255;Tyrphostin AG 1478, free base >99%;AG-1478, 97.5%, a selective EGFR inhibitor;4-(3-Chloroanilino)-6,7-dimethoxyquinazoline;AG 1478;4-Quinazolinamine, N-(3-chlorophenyl)-6,7-dimethoxy-;SUH0SEZ9HY;N-(3-chlorophenyl)-6,7-dimethoxy-quinazolin-4-amine;BRD6408;4-(3-Chloroanilino)-6,7-Dimethoxyquinazoline Hydrochloride EINEC: Molecular Formula：C16H14CLN3O2 Molecular Weight：315.7543
Target:
In Vivo
AG-1478 (AG1478) is irreversible for growth regulation of human lung (A549) and prostate (DU145) cancer cell lines, cultured in chemically defined DMEM/F12 medium. AG-1478 seems to be more effective at lower concentrations, but is unable to completely inhibit growth of A549 cells[1]. Inhibition of EGFR by specific tyrosine kinase inhibitor AG-1478 (AG1478) significantly decreases the angiotensin II-mediated synthesis of TGF-β and fibronectin by cardiac fibroblasts. EGFR is pharmacologically inhibited by small-molecule inhibitor AG-1478 with IC50 of 4 nM[2]. Both Polyfect (PF) and Superfect (SF) treatment lead to increased apoptosis in HEK 293 cells to a similar extent as assessed by flow cytometry. The antioxidant, tempol, significantly reduced dendrimer-mediated apoptosis for both PF and SF. AG-1478 (AG1478), at a 10-fold higher dose (100 μM) than used in signaling studies, is used as a positive control and significantly induced apoptosis in HEK 293 cells[3].
In Vitro
AG-1478 (AG1478) is irreversible for growth regulation of human lung (A549) and prostate (DU145) cancer cell lines, cultured in chemically defined DMEM/F12 medium. AG-1478 seems to be more effective at lower concentrations, but is unable to completely inhibit growth of A549 cells[1]. Inhibition of EGFR by specific tyrosine kinase inhibitor AG-1478 (AG1478) significantly decreases the angiotensin II-mediated synthesis of TGF-β and fibronectin by cardiac fibroblasts. EGFR is pharmacologically inhibited by small-molecule inhibitor AG-1478 with IC50 of 4 nM[2]. Both Polyfect (PF) and Superfect (SF) treatment lead to increased apoptosis in HEK 293 cells to a similar extent as assessed by flow cytometry. The antioxidant, tempol, significantly reduced dendrimer-mediated apoptosis for both PF and SF. AG-1478 (AG1478), at a 10-fold higher dose (100 μM) than used in signaling studies, is used as a positive control and significantly induced apoptosis in HEK 293 cells[3].
Kinase Assay
Cell Assay
Animal Administration
References
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
